A World Allergy Organization International Survey on Diagnostic Procedures and Therapies in Drug Allergy/Hypersensitivity

World Allergy Organization Journal

Pascal Demoly¹  Mario Sanchez-Borges^1,10  Ramon Lleonart²  Anahi Yanez⁷  Marek Kowalski^1,11  Deleanu Diana⁹  Patrizia Bonadonna³  Antonino Romano^1,12  Werner Pichler⁸  Mariana Castells⁵  Rita Mirakian⁴  Bernard Yu-Hor Thong⁶ 

[1] Clinical Department of Allergology, Arnaud de Villeneuve Hospital, University Hospital of Montpellier, Montpellier, France;Allergy Unit, Hospital Universitari Bellvitge Feixa Llarga sn l'Hospitalet, Barcelona, Spain;Allergy Unit, Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy;Cambridge University, NHS Foundation Trust, Allergy Clinic, Cambridge, UK;Division of Rheumatology, Allergy and Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, MA;Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore;Servicio de Alergia e Inmunología Clínica, Hospital Aeronáutico Central, Buenos Aires, Argentina;Division of Allergology, Department of Rheumatology and Allergology/Clinical Immunology, Inselspital, University of Bern, Bern, Switzerland;Department of Allergy, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania;Clinica El Avila, Caracas, Venezuela;Department of Clinical Immunology, Rheumatology, Allergology, Medical University of Lodz, Lodz, Poland;Allergy Unit, Complesso Integrato Columbus, Rome and IRCCS Oasi Maria S.S., Troina, Italy

关键词: skin tests;    hypersensitivity;    drug allergy;    desensitization;   

Others  :  1137717
DOI  :  10.1097/WOX.0b013e31823dc02c

【 摘 要 】

Objective

To study the diagnostic and treatment modalities used in drug allergy/hypersensitivity among members of the World Allergy Organization (WAO).

Methods

A questionnaire comprising 39 questions was circulated electronically to member societies, associate member societies, and regional and affiliate organizations of WAO between June 29, 2009, and August 9, 2009.

Results

Eighty-two responses were received. Skin testing was used by 74.7%, with only 71.4% having access to penicillin skin test reagents. In vitro-specific IgE tests were used by 67.4%, and basophil activation test was used by 54.4%. Lymphocyte transformation tests were used by 36.8% and patch tests by 54.7%. Drug provocation tests were used by 68.4%, the most common indication being to exclude hypersensitivity where history/symptoms were not suggestive of drug hypersensitivity/allergy (76.9%). Rapid desensitization for chemotherapy, antibiotics, or biologic agents was used by 69.6%. Systemic corticosteroid was used in the treatment of Stevens-Johnson syndrome by 72.3%, and high-dose intravenous immunoglobulins in toxic epidermal necrolysis by 50.8%. Human leukocyte antigen screening before prescription of abacavir was used by 92.9% and before prescription of carbamazepine by 21.4%.

Conclusions

Results of this survey form a useful framework for developing educational and training needs and for improving access to drug allergy diagnostic and treatment modalities across WAO member societies.

【 授权许可】

   
2011 World Allergy Organization; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, et al.: Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004, 113:832-836.
• [2]Dietrich JJ, Quinn JM, England RW: Reasons for outpatient consultation in allergy/immunology. Allergy Asthma Proc 2009, 30:69-74.
• [3]England RW, Ho TC, Napoli DC, Quinn JM: Inpatient consultation of allergy/immunology in a tertiary care setting. Ann Allergy Asthma Immunol 2003, 90:393-397.
• [4]Dantonio C, Galimberti M, Barbone B, Calamari M, Airoldi G, et al.: Suspected acute allergic reactions: analysis of admissions to the Emergency Department of the AOU Maggiore della Carità Hospital in Novara from 2003 to 2007. Eur Ann Allergy Clin Immunol 2008, 40:122-129.
• [5]Dietrich JJ, Quinn JM, England RW: Reasons for outpatient consultation in allergy/immunology. Allergy Asthma Proc 2009, 30:69-74.
• [6]Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993, 129:92-96.
• [7]Rzany B, Hering O, Mockenhaupt M, Schröder W, Goerttler E, Ring J, Schöpf E: Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996, 135:6-11.
• [8]Halevy S: Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol 2009, 9:322-328.
• [9]Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, et al.: Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 117:391-397.
• [10]Warner JO, Kaliner MA, Crisci CD, Del Giacco S, Frew AJ, World Allergy Organization Specialty and Training Council, et al.: Allergy practice worldwide: a report by the World Allergy Organization Specialty and Training Council. Int Arch Allergy Immunol 2006, 139:166-174.
• [11]Potter PC, Warner JO, Pawankar R, Kaliner MA, Giacco SD, Rosenwasser L, on behalf of the WAO Specialty and Training Council Recommendations for Competency in Allergy Training for Undergraduates Qualifying as Medical Practitioners: A Position Paper of the World Allergy Organization. WAO J 2009, 2:150-154.
• [12]American Academy of Allergy, Asthma and Immunology: Consultation and referral guidelines citing the evidence: how the allergist-immunologist can help. J Allergy Clin Immunol 2006, 117(2 suppl Consultation):S495-S523.
• [13]Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology, et al.: Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol 2008, 100(3 suppl 3):S1-S148.
• [14]Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczyńska M, Picado C, et al.: EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 2007, 62:1111-1118.
• [15]Aberer W, Bircher A, Romano A, Blanca M, Campi P, European Network for Drug Allergy (ENDA); EAACI Interest Group on Drug Hypersensitivity, et al.: Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003, 58:854-863.
• [16]Mirakian R, Ewan PW, Durham SR, Youlten LJ, Dugué P, BSACI, et al.: BSACI guidelines for the management of drug allergy. Clin Exp Allergy 2009, 39:43-61.
• [17]Torres MJ, Blanca M, European Network for Drug Allergy (ENDA); EAACI Interest Group on Drug Hypersensitivity: Importance of skin testing with major and minor determinants of benzylpenicillin in the diagnosis of allergy to betalactams. Statement from the European Network for Drug Allergy concerning AllergoPen withdrawal. Allergy 2006, 61:910-911.
• [18]Romano A, Blanca M, Torres MJ, Bircher A, EAACI, et al.: Diagnosis of non-immediate reactions to beta-lactam antibiotics. Allergy 2004, 59:1153-1160.
• [19]Torres MJ, Blanca M, Fernandez J, Romano A, Weck A, ENDA; EAACI Interest Group on Drug Hypersensitivity, et al.: Diagnosis of immediate allergic reactions to beta-lactam antibiotics. Allergy 2003, 58:961-972.
• [20]Brockow K, Christiansen C, Kanny G, Clément O, Barbaud A, ENDA; EAACI Interest Group on Drug Hypersensitivity, et al.: Management of hypersensitivity reactions to iodinated contrast media. Allergy 2005, 60:150-158.
• [21]Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academy of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology Ann Allergy Asthma Immunol 1999, 83(6 pt 3):665-700.
• [22]American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology: Contact dermatitis: a practice parameter. Ann Allergy Asthma Immunol 2006, 97(3 suppl 2):S1-38.
• [23]Mertes PM, Laxenaire MC, Lienhart A, Aberer W, Ring J, Pichler WJ, Demoly P, Working Group for the SFAR; ENDA; EAACI Interest Group on Drug Hypersensitivity: Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice. J Investig Allergol Clin Immunol 2005, 15:91-101.
• [24]Barbaud A, Gonçalo M, Bruynzeel D, Bircher A: European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001, 45:321-328.
• [25]Wilkinson DS, Fregert S, Magnusson B, Bandmann HJ, Calnan CD, et al.: Terminology of contact dermatitis. Acta Dermato-Venereologica 1970, 50:287-292.
• [26]Harper NJ, Dixon T, Dugué P, Edgar DM, Fay A, et al.: Working Party of the Association of Anaesthetists of Great Britain and Ireland. Suspected anaphylactic reactions associated with anaesthesia. Anaesthesia 2009, 64:199-211.
• [27]Sturkenboom M, Nicolosi A, Cantarutti L, Mannino S, Picelli G, Scamarcia A, Giaquinto C, NSAIDs Paediatric Research Group: Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics. Pediatrics 2005, 116:e26-e33.
• [28]Rebelo Gomes E, Fonseca J, Araujo L, Demoly P: Drug allergy claims in children: from self-reporting to confirmed diagnosis. Clin Exp Allergy 2008, 38:191-198.
• [29]Ponvert C, Weilenmann C, Wassenberg J, Walecki P, Bourgeois ML, de Blic J, Scheinmann P: Allergy to betalactam antibiotics in children: a prospective follow-up study in retreated children after negative responses in skin and challenge tests. Allergy 2007, 62:42-46.
• [30]Kidon MI, Liew WK, Chiang WC, Lim SH, Goh A, Tang JP, Chay OM: Hypersensitivity to paracetamol in Asian children with early onset of nonsteroidal anti-inflammatory drug allergy. Int Arch Allergy Immunol 2007, 144:51-56.
• [31]Tan VA, Gerez IF, Van Bever HP: Prevalence of drug allergy in Singaporean children. Singapore Med J 2009, 50:1158-1161.
• [32]Caubet JC, Kaiser L, Lemaître B, Fellay B, Gervaix A, Eigenmann PA: The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. JAllergy Clin Immunol 2011, 127:218-222.
• [33]Ponvert C, Perrin Y, Bados-Albiero A, Le Bourgeois M, Karila C, et al.: Allergy to betalactam antibiotics in children: results of a 20-year study based on clinical history, skin and challenge tests. Pediatr Allergy Immunol 2011, 22:411-418.
• [34]Matheu V, Pérez-Rodriguez E, Sánchez-Machin I, de la Torre F, García-Robaina JC: Major and minor determinants are high-performance skin tests in beta-lactam allergy diagnosis. J Allergy Clin Immunol 2005, 116:1167-1168.
• [35]Bousquet PJ, Co-Minh HB, Arnoux B, Daures JP, Demoly P: Importance of minor determinants and benzylpenicilloyl poly-L-lysine skin testing in the diagnosis of beta-lactam allergy. J Allergy Clin Immunol 2005, 115:1314-1316.
• [36]Matheu V, Pérez E, González R, Poza P, de la Torre F, Sánchez-Machín I, García-Robaina JC: Assessment of a new brand of determinants for skin testing in a large group of patients with suspected betalactam allergy. J Investig Allergol Clin Immunol 2007, 17:257-260.
• [37]Romano A, Viola M, Bousquet PJ, Gaeta F, Valluzzi R, Caruso C, Demoly P: A comparison of the performance of two penicillin reagent kits in the diagnosis of beta-lactam hypersensitivity. Allergy 2007, 62:53-58.
• [38]Barbaud A: Skin testing in delayed reactions to drugs. Immunol Allergy Clin North Am 2009, 29:517-535.
• [39]Friedmann PS, Ardern-Jones M: Patch testing in drug allergy. Cur Op Allergy Clin Immunol 2010, 10:291-296.
• [40]Lochmatter P, Zawodniak A, Pichler WJ: In vitro tests in drug hypersensitivity diagnosis. Immunol Allergy Clin North Am 2009, 29:537-554.
• [41]Aberer W, Kränke B: Provocation tests in drug hypersensitivity. Immunol Allergy Clin North Am 2009, 29:567-584.
• [42]Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P: Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004, 140:1001-1006.
• [43]Blanca-López N, Zapatero L, Alonso E, Torres MJ, Fuentes V, Martínez-Molero MI, Blanca M: Skin testing and drug provocation in the diagnosis of nonimmediate reactions to aminopenicillins in children. Allergy 2009, 64:229-233.
• [44]Bousquet PJ, Pipet A, Bousquet-Rouanet L, Demoly P: Oral challenges are needed in the diagnosis of beta-lactam hypersensitivity. Clin Exp Allergy 2008, 38:185-190.
• [45]Torres MJ, Mayorga C, Leyva L, Guzman AE, Cornejo-García JA, Juarez C, Blanca M: Controlled administration of penicillin to patients with a positive history but negative skin and specific serum IgE tests. Clin Exp Allergy 2002, 32:270-276.
• [46]Caimmi S, Galéra C, Bousquet-Rouanet L, Arnoux B, Demoly P, Bousquet PJ: Safety of cefuroxime as an alternative in patients with a proven hypersensitivity to penicillins: a DAHD Cohort Survey. Int Arch Allergy Immunol 2010, 153:53-60.
• [47]Bavbek S, Dursun AB, Eryilmaz A, Misirligil Z: Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study. Int Arch Allergy Immunol 2007, 142:64-69.
• [48]El Miedany Y, Youssef S, Ahmed I, El Gaafary M: Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006, 97:105-109.
• [49]Celik G, Erkekol FO, Bavbek S, Dursun B, Misirligil Z: Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance. Ann Allergy Asthma Immunol 2005, 95:33-37.
• [50]Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A: Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005, 95:154-158.
• [51]Muratore L, Ventura M, Calogiuri G, Calcagnile F, Quarta E, Muratore M, Ferrannini A: Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2007, 98:168-171.
• [52]Castells M: Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am 2009, 29:585-606.
• [53]Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, European Network of Drug Allergy and the EAACI Interest Group on Drug Hypersensitivity, et al.: General considerations on rapid desensitization for drug hypersensitivity--a consensus statement. Allergy 2010, 65:1357-1366.
• [54]Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology: Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010, 105:259-273.
• [55]Macy E, Bernstein JA, Castells MC, Gawchik SM, Lee TH, et al.: Aspirin Desensitization Joint Task Force. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol 2007, 98:172-174.
• [56]Wong JT, Nagy CS, Krinzman SJ, Maclean JA, Bloch KJ: Rapid oral challenge-desensitization for patients with aspirin-related urticaria-angioedema. J Allergy Clin Immunol 2000, 105:997-1001.
• [57]Silberman S, Neukirch-Stoop C, Steg PG: Rapid desensitization procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005, 95:509-510.
• [58]Rossini R, Angiolillo DJ, Musumeci G, Scuri P, Invernizzi P, Bass TA, Mihalcsik L, Gavazzi A: Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. Am J Cardiol 2008, 101:786-789.
• [59]French LE: Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006, 55:9-16.
• [60]Wolf R, Davidovici B: Severe cutaneous adverse drug reactions: who should treat, where and how: Facts and controversies. Clin Dermatol 2010, 28:344-348.
• [61]Gerull R, Nelle M, Schaible T: Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med 2011, 39:1521-1532.
• [62]Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, Heng WJ: Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 2007, 62:527-531.
• [63]Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS: Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol 2010, 10:280-290.
• [64]Mallal S, Phillips E, Carosi G, Molina JM, Workman C, PREDICT-1 Study Team, et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
• [65]Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006, 16:297-306.
• [66]Hung SI, Chung WH, Liou LB, Chu CC, Lin M, et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005, 102:4134-4139.
• [67]Fernando SL, Broadfoot AJ: Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening. CMAJ 2010, 182:476-480.
• [68]Gomes ER, Pichler WJ, Demoly P, Aberer W, Frew AJ, DeWeck A, the EAACI Interest Group on Drug Hypersensitivity: The Drug Ambassador Project. The diversity of diagnostic procedures for drug allergy around Europe. Allergy Clin Immunol 2005, 17:9-18.